Further, GDF15 knockdown significantly inhibits invasion of HER2-overexpressing and triple-negative breast cancer cells, supporting further preclinical investigation of GDF15-targeted therapies. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.